Comparing the current results to its competitors, Bluebird Bio Inc reported Revenue increase in the 1 quarter 2025 by 108.43 % year on year. The sales growth was above Bluebird Bio Inc 's competitors' average revenue growth of 26.25 %, achieved in the same quarter.
August 24, 2024
In a significant announcement that underscores the challenges facing Bluebird Bio, Inc. (Nasdaq: BLUE), the company reported on August 20, 2024, that it has received formal notices from The Nasdaq Stock Market signaling non-compliance with listing rules due to delayed financial reporting. Specifically, Bluebird Bio has yet to file its Quarterly Reports on Form 10-Q for both the first and second quarters of 2024, impacting its adherence to Nasdaq Listing Rule 5250(c)(1), which mandates timely filing of financial statements.The timing of this announcement could not be more critical. With Bluebird Bio s shares trailing broader market performance throughout August, the company s year-to-date performance shows a ...
August 14, 2024
SOMERVILLE, Mass. bluebird bio, Inc. (NASDAQ: BLUE) today announced its financial results for the second quarter, ending June 30, 2024, alongside significant developments in its commercial and operational activities. The Company’s accelerating momentum in the commercial launch of its gene therapy products brings renewed optimism and strategic clarity as it aims to reshape the landscape of genetic disease treatment. Impressive Commercial Trajectory bluebird bio has demonstrated robust progress in its commercial endeavors, evidenced by the completion of over 20 cell collections for patients suffering from sickle cell disease (SCD) and beta-thalassemia in 2024. This milestone is particularly significant as i...
May 29, 2024
bluebird bio Strengthens Leadership Team with Appointment of O. James Sterling as Chief Financial Officer bluebird bio, Inc. (Nasdaq: BLUE), a pioneering gene therapy company, has announced the appointment of O. James Sterling as its Chief Financial Officer (CFO), effective June 10, 2024. This strategic move underscores the company s commitment to bolstering its financial leadership as it continues to advance its innovative therapies for severe genetic diseases.Mr. Sterling brings a wealth of experience to bluebird bio, having most recently served as CFO at Renalytix plc. Renalytix is a prominent diagnostics company with a focus on the clinical management of kidney disease. During his tenure at Renalytix, St...
May 17, 2024
Bluebird Bio Faces Lawsuit Over Failure to Comply with Nasdaq Listing RuleOn May 28, 2024, the law firm of Kirby McInerney LLP announced the upcoming deadline for investors to seek the role of lead plaintiff in a federal securities class action against bluebird bio, Inc. The lawsuit was filed on behalf of those who acquired Blue s securities between April 24, 2023, and December 8, 2023, inclusive. The lawsuit alleges that Bluebird Bio failed to comply with Nasdaq Listing Rule 5250(c)(1) by not filing its Annual Report on Form 10-K for the year ended December 31, 2023, thereby causing significant financial harm to investors.Bluebird Bio, a biotechnology company focused on gene therapy treatments, announced on...
April 26, 2024
In recent developments associated with listed biotechnology firms, bluebird bio, Inc., a leading expert in gene therapy, announced on April 24, 2024, that they had received an anticipatory notice from the Nasdaq Stock Market LLC (Nasdaq). The notice indicated that the Nasdaq has identified the company s non-compliance with the Nasdaq Listing Rule 5250(c)(1) due to its failure to file the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the 2023 Form 10-K).Nasdaq Listing Rule 5250(c)(1) insists on the duty and punctuality of listed entities filing all obligatory periodic financial reports. Known for its pioneering endeavors in utilizing gene therapy to tackle hereditary diseases and can...
March 18, 2024
Bluebird Bio Secures Debt Financing to Support Commercial Launches of Gene TherapiesBluebird Bio, a leading biotechnology company, has announced that it has secured a $175 million five-year term loan facility with Hercules Capital. This debt financing will strengthen the company s balance sheet as it focuses on the commercial launches of its three FDA-approved gene therapies: LYFGENIA for sickle cell disease, ZYNTEGLO for beta-thalassemia, and SKYSONA for cerebral adrenoleukodystrophy.The gene therapy program for transfusion-dependent beta-thalassemia, known as beti-cel, has shown promising results in achieving durable transfusion independence and normal or near-normal adult hemoglobin levels. Updated data f...
In a groundbreaking announcement, bluebird bio inc. presented updated data from its gene therapy program at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data showcased the promising potential of beti-cel as a curative gene therapy for patients with transfusion-dependent (TDT) beta-thalassemia, demonstrating durable transfusion independence and the attainment of normal or near-normal adult hemoglobin (Hb) levels. This update not only provides hope for patients but also showcases the efficacy and benefits of this cutting-edge treatment. Thalassemia is an inherited blood disorder that affects the production of hemoglobin, leading to the reduced ability of red blood c...
In a recent announcement, Bluebird Bio Inc., a biotechnology company based in Massachusetts, revealed promising data from their gene therapy program for the treatment of sickle cell disease. The results, presented at the 65th American Society of Hematology conference, showcased the long-term efficacy, safety, and quality of life improvements observed in patients who received lovotibeglogene autotemcel (lovo-cel) gene therapy. Additionally, as Bluebird Bio Inc. unveiled remarkable revenue growth in the third quarter of 2023, this article highlights the company s noteworthy achievements in both medical advancements and business success. Gene Therapy Program for Sickle Cell Disease: The Phase ...
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.
Sana Biotechnology Inc operates as a biotechnology company that focuses on developing and commercializing cellular therapies for various diseases. Their business model involves leveraging innovative technologies and collaborations with clinical and industry partners to develop advanced medical treatments.
Cargo Therapeutics Inc is a biotechnology company that utilizes a unique business model focused on developing targeted therapeutics. Their approach involves engineering cell-penetrating peptides to deliver various cargoes, such as gene therapies or small molecules, directly to specific cells or tissues, increasing precision and effectiveness of treatments. By leveraging this technology, the company aims to address unmet medical needs with potentially transformative therapies.
Sources:
Bluebird Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bluebird Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
